Patents by Inventor James P. Gregson

James P. Gregson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
    Patent number: 11261251
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: March 1, 2022
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITY
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR
    Publication number: 20200172616
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: July 9, 2019
    Publication date: June 4, 2020
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITY
    Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
  • Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
    Patent number: 10370448
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-1, and/or PD-L2 activity (e.g., persistent infectious diseases autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: August 6, 2019
    Assignees: EMORY UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR
    Publication number: 20180371084
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-1, and/or PD-L2 activity (e.g., persistent infectious diseases autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 27, 2018
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITY
    Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
  • Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
    Patent number: 10011656
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: July 3, 2018
    Assignees: EMORY UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • Humanized antibodies to iNKT
    Patent number: 9932402
    Abstract: Methods of treatment to suppress an immune response are provided. The method comprises administering to a subject in need of treatment a naked blocking antibody that binds selectively iNKT cells in an amount effective to suppress the subject's iNKT cell function. Compositions comprising, an isolated, humanized antibody that binds selectively iNKT cells are also provided.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 3, 2018
    Assignee: NKT Therapeutics Inc.
    Inventors: Alemseged Truneh, Francis Joseph Carr, Timothy David Jones, James P. Gregson
  • HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR
    Publication number: 20160137731
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: August 10, 2015
    Publication date: May 19, 2016
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITY
    Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
  • Human anti-PD-1 antibodies and uses therefor
    Patent number: 9102727
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 11, 2015
    Assignees: EMORY UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR
    Publication number: 20130291136
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 31, 2013
    Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
  • Anti-PD-L1 antibodies and uses therefor
    Patent number: 8552154
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: October 8, 2013
    Assignees: Emory University, Dana-Farber Cancer Institute, Inc.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR
    Publication number: 20110271358
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: September 25, 2009
    Publication date: November 3, 2011
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson